Afficher la notice abrégée

dc.creatorOeconomou, A.en
dc.creatorMelekos, M.en
dc.creatorMadersbacher, H.en
dc.date.accessioned2015-11-23T10:41:39Z
dc.date.available2015-11-23T10:41:39Z
dc.date.issued2009
dc.identifier10.1016/j.eururo.2009.04.003
dc.identifier.issn3022838
dc.identifier.urihttp://hdl.handle.net/11615/31467
dc.source.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-65749105964&partnerID=40&md5=36e91746125623a7cb058f3eebf9193c
dc.subjectalpha adrenergic receptor blocking agenten
dc.subjectbotulinum toxin Aen
dc.subjectplaceboen
dc.subjectprostate specific antigenen
dc.subjectsteroid 5alpha reductase inhibitoren
dc.subjectantineoplastic activityen
dc.subjectclinical trialen
dc.subjectdrug effecten
dc.subjectdrug safetyen
dc.subjectdrug treatment failureen
dc.subjectfollow upen
dc.subjecthumanen
dc.subjectletteren
dc.subjectlower urinary tract symptomen
dc.subjectmicturitionen
dc.subjectpatient satisfactionen
dc.subjectpelvic organ prolapseen
dc.subjectpriority journalen
dc.subjectprostate hypertrophyen
dc.subjectrepeated drug doseen
dc.subjectsingle drug doseen
dc.subjecttransurethral resectionen
dc.subjecturine flow rateen
dc.titleReply to Giuseppe Brisinda, Serafino Vanella and Giorgio Maria's Letter to the Editor re: Athanassios Oeconomou, Helmut Madersbacher, Gustav Kiss, Thomas J. Berger, Michael Melekos and Peter Rehder. Is Botulinum Neurotoxin Type A (BoNT-A) a Novel Therapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement? A Review of the Literature. Eur Urol 2008;54:765-77en
dc.typejournalArticleen


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée